Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
JSPR

JSPR - Jasper Therapeutics, Inc. Stock Price, Fair Value and News

21.53USD+1.61 (+8.08%)Market Closed

Market Summary

JSPR
USD21.53+1.61
Market Closed
8.08%

JSPR Stock Price

View Fullscreen

JSPR RSI Chart

JSPR Valuation

Market Cap

324.8M

Price/Earnings (Trailing)

-5.08

Price/Sales (Trailing)

81

EV/EBITDA

-76.78

Price/Free Cashflow

-5.65

JSPR Price/Sales (Trailing)

JSPR Profitability

Return on Equity

-56.46%

Return on Assets

-50.76%

Free Cashflow Yield

-17.7%

JSPR Fundamentals

JSPR Revenue

Revenue (TTM)

4.0M

Rev. Growth (Yr)

26.46%

Rev. Growth (Qtr)

-3.48%

JSPR Earnings

Earnings (TTM)

-63.9M

Earnings Growth (Yr)

3.73%

Earnings Growth (Qtr)

17.21%

Breaking Down JSPR Revenue

Last 7 days

1.0%

Last 30 days

-13.9%

Last 90 days

-9.6%

Trailing 12 Months

48.5%

How does JSPR drawdown profile look like?

JSPR Financial Health

Current Ratio

13.49

JSPR Investor Care

Shares Dilution (1Y)

193.44%

Diluted EPS (TTM)

-5.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20244.0M000
20230000
20220000
20190000

Tracking the Latest Insider Buys and Sells of Jasper Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 12, 2024
mahal jeetinder singh
acquired
6,390
7.1
900
chief operating officer
Jun 12, 2024
mahal jeetinder singh
sold
-21,739
24.155
-900
chief operating officer
Jun 07, 2024
tucker edwin jonathan
acquired
1,669
4.1735
400
chief medical officer
Mar 12, 2024
mahal jeetinder singh
acquired
6,390
7.1
900
chief operating officer
Mar 12, 2024
mahal jeetinder singh
sold
-23,792
26.4358
-900
chief operating officer
Feb 08, 2024
carlyle group inc.
bought
2,460,500
12.95
190,000
-
Feb 08, 2024
velan capital investment management lp
bought
4,532,500
12.95
350,000
-
Nov 28, 2023
wiggans thomas g
bought
6,486
0.6486
10,000
-
Nov 21, 2023
wiggans thomas g
bought
6,383
0.6383
10,000
-
Nov 20, 2023
wiggans thomas g
bought
6,309
0.6309
10,000
-

1–10 of 40

Which funds bought or sold JSPR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 09, 2024
LAZARD ASSET MANAGEMENT LLC
sold off
-100
-8,000
-
-%
Jul 09, 2024
LAZARD ASSET MANAGEMENT LLC
new
-
21,000
21,000
-%
Jun 04, 2024
ZAZOVE ASSOCIATES LLC
sold off
-100
-5,000
-
-%
May 29, 2024
Opaleye Management Inc.
sold off
-100
-3,144,430
-
-%
May 29, 2024
Opaleye Management Inc.
new
-
12,788,400
12,788,400
2.79%
May 20, 2024
Virtu Financial LLC
new
-
306,000
306,000
0.02%
May 17, 2024
Ikarian Capital, LLC
new
-
3,087,940
3,087,940
0.34%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-8,844
-
-%
May 16, 2024
JANE STREET GROUP, LLC
new
-
1,230,010
1,230,010
-%
May 15, 2024
Man Group plc
new
-
597,682
597,682
-%

1–10 of 49

Are Funds Buying or Selling JSPR?

Are funds buying JSPR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own JSPR
No. of Funds

Unveiling Jasper Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 27, 2024
avidity partners management lp
5.1%
760,000
SC 13G
Feb 14, 2024
biotechnology value fund l p
-
0
SC 13G/A
Feb 14, 2024
qiming u.s. healthcare fund ii, l.p.
6.2%
928,964
SC 13G/A
Feb 14, 2024
citadel advisors llc
0.0%
6
SC 13G/A
Feb 12, 2024
carlyle group inc.
7.1%
1,066,189
SC 13D/A
Feb 09, 2024
velan capital investment management lp
7.9%
1,188,500
SC 13D/A
Feb 05, 2024
sphera funds management ltd.
6.39%
7,130,625
SC 13G/A
Feb 02, 2024
soleus capital master fund, l.p.
8.8%
987,096
SC 13G/A
Oct 10, 2023
sphera funds management ltd.
5.13%
5,687,134
SC 13G
Feb 27, 2023
velan capital investment management lp
7.7%
8,385,000
SC 13D

Recent SEC filings of Jasper Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Jun 20, 2024
3
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
8-K
Current Report
Jun 12, 2024
144
Notice of Insider Sale Intent
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
8-K
Current Report
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading

Peers (Alternatives to Jasper Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
48.0B
6.8B
-10.56% 2.15%
-8.04
7.01
-64.45% -224.75%
31.6B
2.0B
55.73% 23.15%
-95.14
15.77
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.3B
2.5B
2.83% -0.92%
79.36
6.6
13.74% 186.89%
14.4B
3.8B
3.06% 4.80%
19.28
3.81
8.58% 129.81%
MID-CAP
5.5B
107.9M
4.99% -8.71%
-10.01
48.09
54.84% -28.31%
5.0B
524.1M
-2.02% -21.56%
-11.97
9.53
394.93% 39.61%
4.0B
251.0M
15.33% 15.88%
-13.61
16.07
73.58% -86.73%
3.7B
240.7M
14.36% -14.84%
-7.76
12.77
-1.03% -213.92%
3.1B
813.8M
24.88% -44.36%
-1.8K
3.78
56.43% 98.83%
2.3B
996.6M
14.03% 101.23%
-5.78
2.31
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
12.68% 25.98%
30.78
4.87
60.38% -34.49%
644.1M
881.7K
20.30% 675.68%
-19.08
481.06
-77.61% 33.36%
288.6M
4.2M
22.55% 71.91%
-2.31
69.39
-66.30% 48.24%
18.5M
2.1M
-16.02% -80.80%
-0.8
7.61
-13.45% 69.54%

Jasper Therapeutics, Inc. News

Latest updates
MarketBeat10 Jul 202408:39 pm

Jasper Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q22023Q12022Q22022Q12019Q4
Revenue-3.5%1,386,0001,436,0001,096,00092,000--
Operating Expenses-15.5%15,072,00017,827,00013,947,00011,963,00012,778,000-
  S&GA Expenses5.4%4,774,0004,530,0004,142,0003,828,0004,590,000-
  R&D Expenses-22.6%10,298,00013,297,0009,805,0008,135,0008,188,000-
Interest Expenses100.0%--109,000-70,000-3,000-74,000-
EBT Margin-------3.75
Net Income14.6%-13,728,000-16,080,000-14,260,000-10,404,000-2,207,000-595,380
Net Income Margin-Infinity%-15.94--11.35---3.86
Free Cashflow-18.6%-15,736,000-13,272,000-10,335,000-9,356,000-14,213,000-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets32.7%12695.0011012413948.0059.0070.0081.0094.0010710110123.00101102102102
  Current Assets35.3%12089.0010511913342.0052.0063.0074.0088.001020.001.0021.001.001.001.002.00
    Cash Equivalents36.4%11887.0010411613039.0051.0061.0071.0085.0010117.0024.0020.0015.001.001.0027.00
  Net PPE-9.6%2.003.003.003.003.004.004.004.003.004.003.003.00-1.00----
Liabilities-22.6%13.0016.0016.0014.0014.0012.0012.0012.0012.0024.0029.0014.0011.0015.004.004.004.0011.00
  Current Liabilities-27.9%9.0012.0012.009.008.007.007.007.006.008.009.000.000.004.000.000.000.000.00
Shareholder's Equity44.4%11378.0094.0011012536.0048.0059.0068.0070.0079.005.002.005.005.005.005.005.00
  Retained Earnings-8.1%-183-169-153-135-119-105-91.92-80.06-69.66-67.45-58.39-5.15-1.58-36.81-0.44-0.240.00-0.60
  Additional Paid-In Capital19.6%29724824724624514113913913813713710.007.002.005.005.005.006.00
Shares Outstanding35.1%15.0011.0011.0011.009.004.004.004.004.004.000.00--0.000.00--0.00
Float----111---49.00---99.00---103--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Cashflow From Operations4.4%-15,736-16,467-11,993-13,307-10,300-12,688-9,643-9,356-14,213-14,584-7,108-5,791-6,195-5,393-12,467-173-232-
  Share Based Compensation0.9%1,1691,1581,3951,3911,2671,6046441,065778231195295327437316---
Cashflow From Investing89.1%-25.00-230--11.00-26.00-82.00-222-243-29.00-711-470-287-96018.0072.0031.0077.00-
Cashflow From Financing17572.0%47,349-27136.00-305101,51128.001.0013.0013.00-90991,726-60010,75210,803----
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

JSPR Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses  
Research and development$ 10,298$ 9,805
General and administrative4,7744,142
Total operating expenses15,07213,947
Loss from operations(15,072)(13,947)
Interest income1,3861,096
Change in fair value of earnout liability(20)(764)
Change in fair value of common stock warrant liability(575)
Other expense, net(22)(70)
Total other income (expense), net1,344(313)
Net loss and comprehensive loss$ (13,728)$ (14,260)
Net loss per share attributable to common stockholders, basic (in Dollars per share)$ (1.03)$ (1.62)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in Shares)13,334,9008,787,756

JSPR Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 118,475$ 86,887
Prepaid expenses and other current assets1,8332,051
Total current assets120,30888,938
Property and equipment, net2,4642,727
Operating lease right-of-use assets1,3511,467
Restricted cash417417
Other non-current assets1,4231,343
Total assets125,96394,892
Current liabilities:  
Accounts payable2,3914,149
Current portion of operating lease liabilities1,000972
Earnout liability20
Accrued expenses and other current liabilities5,5057,253
Total current liabilities8,91612,374
Non-current portion of operating lease liabilities1,5531,814
Other non-current liabilities2,2642,264
Total liabilities12,73316,452
Commitments and contingencies (Note 8)
Stockholders’ equity  
Preferred stock: $0.0001 par value — 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; none issued and outstanding at March 31, 2024 and December 31, 2023
Common stock: $0.0001 par value — 492,000,000 shares authorized at March 31, 2024 and December 31, 2023; 15,085,553 and 11,163,896 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively21
Additional paid-in capital296,556248,039
Accumulated deficit(183,328)(169,600)
Total stockholders’ equity113,23078,440
Total liabilities and stockholders’ equity$ 125,963$ 94,892
JSPR
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
 CEO
 WEBSITEjaspertherapeutics.com/
 INDUSTRYBiotechnology
 EMPLOYEES35

Jasper Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Jasper Therapeutics, Inc.? What does JSPR stand for in stocks?

JSPR is the stock ticker symbol of Jasper Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Jasper Therapeutics, Inc. (JSPR)?

As of Tue Jul 16 2024, market cap of Jasper Therapeutics, Inc. is 324.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JSPR stock?

You can check JSPR's fair value in chart for subscribers.

What is the fair value of JSPR stock?

You can check JSPR's fair value in chart for subscribers. The fair value of Jasper Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Jasper Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for JSPR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Jasper Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether JSPR is over valued or under valued. Whether Jasper Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Jasper Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JSPR.

What is Jasper Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jul 16 2024, JSPR's PE ratio (Price to Earnings) is -5.08 and Price to Sales (PS) ratio is 81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JSPR PE ratio will change depending on the future growth rate expectations of investors.